dihexa aqueous solubility ph dependent of di-(2-ethylhexyl)phosphoric acid (D2EHPA) in electrolyte solutions: Studies relevant to liquid-liquid extraction dihexa aqueous solubility ph dependent
Description
The only human trial ever registered (NCT02637284) was cancelled in 2016 without publishing results
CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process
However, the IM route was the top-ranked statistically, followed by the SL and then the oral routes, but without clinical significance
Compared to conventional radiotherapy, stereotactic radiotherapy appears to have lower complication rates (42)
